重组改构人肿瘤坏死因子经胸腔注射治疗恶性胸腔积液41例临床疗效研究

Clinical Efficacy of Malignant Pleural Effusion Treatment with Recombinant Human Tumor Necrosis Factor by Thoracic Cavity Injection

目的探讨重组改构人肿瘤坏死因子注射液胸腔注射治疗恶性胸腔积液的临床疗效与不良反应。方法临床选择41例经CT引导下肿块穿刺或支气管镜病理学活检及胸水脱落细胞学检查证实为恶性肿瘤胸腔积液的患者,随机分为两组,治疗组进行重组改构人肿瘤坏死因子注射液胸腔注射治疗+全身化疗,对照组仅进行全身化疗,观察其疗效与毒副反应。结果 41例患者治疗结束后4周进行疗效评估,治疗组及对照组总有效率分别为52.38%、30.00%,治疗组高于对照组,但差异无统计学意义(P>0.05),两组患者治疗过程中均无严重不良反应,无Ⅱ度及以上血液学毒性反应。未发生治疗相关性死亡。结论重组改构人肿瘤坏死因子注射液胸腔注射治疗恶性胸腔积液疗效确切、并发症少、安全性高、患者耐受性好。

Objective To study the clinical effect and adverse reaction of the recomhinam human tumor necrosis factor on malignant pleural effusion by thoracic cavity injection. Methods 41 clinical patients had been diagnosed as malignant pleural effusion by CT-guided tumor puncture, bronchoscopy pathological biopsy and pleural effusion cytology. They were randomly divided into the experimental group and the control group. The experimental group was given recombinant human tumor necrosis factor by thoracic cavity injection and the control group systemic chemotherapy. Observing the efficacy of the two groups. Results The curative effect of the two groups was evaluated after four-week treatment. Total effective rate was respectively 52.38% and 30% in the experimental group and the control group. But the effective rate of the experimental group was higher than that of the control group. There were no serious adverse reactions and no hematological toxicity over Ⅱ degree in both groups. No treatment related death occurred. Conclusion Recombinant human tumor necrosis factor by thoracic cavity injection is effective to treat malignant pleural effusion. It is safe and well tolerated.